Early, delayed, or combined contrast-enhanced mammography for detecting residual disease after neoadjuvant chemotherapy in breast cancer - PubMed
a day ago
- #Neoadjuvant Chemotherapy
- #Contrast-Enhanced Mammography
- #Breast Cancer
- Contrast-enhanced mammography (CEM) evaluated for detecting residual disease (RD) after neoadjuvant chemotherapy (NAC) in breast cancer.
- Delayed CEM acquisitions showed higher sensitivity (85.7%) and negative predictive value (71.2%) for RD compared to early acquisitions (68.1% sensitivity, 58.2% NPV).
- Early CEM acquisitions provided slightly better agreement with pathological tumor size (mean difference 5.7 mm) than delayed acquisitions (11.8 mm).
- Combined CEM protocol (early and delayed) had sensitivity of 86.6%, similar to delayed-only.
- Inclusion of delayed images in post-NAC CEM improves detection of residual invasive disease, aiding surgical planning.